Oxygen & Hyperbaric - Evidence & uses
Approved uses vs emerging longevity claims
Last updated 3 October 2026. How we write this .
HBOT has recognised uses for specific medical conditions, but longevity claims remain unproven. Clinical acceptance, regulatory status and NHS funding mean different things.
Start here HBOT has recognised uses for specific medical conditions, but longevity claims remain unproven. Clinical acceptance, regulatory status and NHS funding mean different things.
By the end, you will understand What HBOT changes in the body What does 'approved' actually mean? The established side in a UK context Key words used in this lesson Hyperbaric Above normal atmospheric pressure. Hyperbaric oxygen therapy involves breathing oxygen in a pressurised chamber, which increases the amount dissolved in the blood. Full plain-English glossary
Where this information comes from Claim-cited evidence. Central research claims on this lesson are linked to specific studies or official guidance.
This lesson links the specific studies and guidance used for its central claims.
Our standard: expert or athlete opinion may illustrate a viewpoint, but it is never treated as proof. Read the editorial policy .
Report an error or outdated claim .
Hyperbaric oxygen therapy, or HBOT, has recognised clinical uses for specific medical conditions, while claims about longer life, rejuvenation and general performance remain unproven. The distinction matters, but recognised uses do not all have equally strong evidence. A useful assessment separates the clinical problem, the evidence for meaningful benefit, and what an organisation has actually approved or recommended.
What HBOT changes in the body
HBOT combines an environment above normal atmospheric pressure with increased oxygen availability inside a specialised chamber. Most oxygen in blood normally travels attached to haemoglobin, the oxygen-carrying protein in red blood cells. Higher oxygen pressure increases the amount dissolved directly in plasma, the liquid part of blood, and can increase oxygen delivery to tissues.
Pressure also has a physical effect on gas bubbles. In decompression illness and gas embolism, bubbles can disrupt circulation and damage tissues. Recompression can reduce bubble volume, while oxygen supports tissues whose supply has been interrupted. This gives these applications a direct connection between the underlying problem and the intervention.
Other proposed effects involve oxygen-sensitive signals that influence blood vessel growth, immune activity and tissue repair. Laboratory and animal experiments help explain these possibilities, but showing that a pathway changes does not establish a useful outcome in humans. Healthy tissues are not necessarily limited by oxygen availability, so increasing oxygen does not automatically improve their function.
What does 'approved' actually mean?
An indication is a defined clinical reason for an intervention. However, regulatory permission for a device, recognition by a specialist society, a clinical guideline recommendation and NHS funding are different decisions. An advertisement may use the word 'approved' without explaining which decision it means or which patient group it covers.
A device meeting regulatory requirements does not establish every benefit claimed by a business using it. Equally, a specialist organisation recognising a particular indication does not mean that every country funds that use. Regulatory status and guidance can change, and arrangements differ between countries, including within the UK.
The relevant questions are therefore precise: which organisation made the decision, for which condition, and under what clinical circumstances? Recognition for a narrowly defined medical problem cannot be extended to general wellbeing simply because the same chamber is involved. Qualifications and professional oversight matter for safety, but they do not independently prove a longevity claim.
The established side in a UK context
NHS England commissions HBOT for clinically appropriate cases of decompression illness and gas embolism. These are specific medical situations managed through specialist pathways. They are not broad categories such as tiredness, ageing or recovery, and their clinical importance should not be used as evidence for unrelated applications.
The basis for established practice is more nuanced than saying that every recognised use has large, definitive trials. For decompression illness and gas embolism, accumulated clinical experience, observational evidence, physical mechanisms and specialist consensus are important. Randomised comparisons that withhold accepted emergency care can be difficult or ethically problematic. Strong clinical acceptance and high-certainty trial evidence are related concepts, but they are not interchangeable.
International specialist lists can be broader. The Undersea and Hyperbaric Medical Society recognises selected applications involving radiation injury, problem wounds and other named conditions. Those lists are not NHS funding policies. NICE guidance on diabetic foot problems, for example, restricts HBOT for diabetic foot ulcers to clinical trials. This illustrates why an overseas list cannot answer a UK access or suitability question.
Recognised uses still need evidence grading
Decades of use provide experience, but time alone does not settle effectiveness. Different conditions have different evidence bases, and benefits may depend on the tissue affected, the severity of damage and the other care provided. Where HBOT is an additional intervention, the relevant question is what it adds to that existing care.
A Cochrane review of late radiation tissue injury found possible benefits in selected tissues and patient groups, with low- to moderate-certainty evidence for several outcomes. Limitations included small studies, incomplete reporting and uncertainty about the size of benefit. This is a more accurate description than either 'proven for all radiation damage' or 'no evidence at all'.
Funding decisions also consider practical delivery and value for money. Lack of routine funding does not prove that an intervention has no biological effect. Conversely, availability in a private clinic does not establish effectiveness. Evidence, clinical judgement and funding policy overlap, but each answers a different question.
A claim's category helps set expectations, but it is only the starting point. Evidence must still match the specific condition, population and outcome being claimed.
What emerging longevity research shows
Longevity research asks a different question from emergency medicine: can HBOT help people maintain function, avoid age-related illness or live longer? Existing human research does not establish longer lifespan or a durable, broad extension of healthy life. Some early findings justify further investigation, but they do not support presenting rejuvenation as an established outcome.
One small prospective human study reported changes in telomere length and markers associated with cellular senescence in selected blood cells. Telomeres are protective structures at chromosome ends; senescence describes a cellular state involving persistent changes in function and division. The study lacked a separate control group, and its measurements did not demonstrate that participants lived longer or that their organs became younger.
Blood biomarkers describe particular samples, not the whole person. A change in a cell population can reflect shifts in which cells are present as well as changes within cells. Even a reliable laboratory difference needs a demonstrated connection to outcomes that matter, such as preserved independence or fewer serious illnesses.
Recovery and performance claims need their own evidence. A finding in injured tissue does not establish faster recovery in healthy athletes, and a short-term change in a test does not establish sustained sporting improvement. The companion lesson, Reading small, early HBOT studies critically, examines study design in greater detail; here, the central issue is whether the evidence answers the advertised question.
Who the evidence applies to
People with a specific diagnosed indication, people participating in research and healthy consumers are distinct populations. They have different baseline risks and different potential benefits. Results from carefully selected older volunteers cannot automatically be generalised to younger adults, people with multiple illnesses or everyone experiencing changes associated with ageing.
The intervention must also match. Services described as 'mild hyperbaric' may differ from clinical HBOT in their equipment and oxygen environment. Sharing a name or a chamber-like appearance does not make them equivalent. Evidence from one setting cannot simply be transferred to another without research supporting that transfer.
People with diabetes should discuss questions about HBOT with their diabetes care team, particularly where wounds are involved. They should not change medicines based on a consumer device or its readings. A wellness assessment cannot replace the clinical assessment of circulation, infection or other factors that influence wound healing.
Safety is part of the comparison
HBOT can cause pressure-related ear or sinus injury and temporary changes in vision. Oxygen exposure can also cause toxicity, including seizures, and oxygen-rich environments create a fire hazard. Specialist assessment, suitable facilities and trained supervision address risks; describing an intervention as non-invasive does not make it risk-free.
Pain in the ears or chest, breathing difficulty or feeling suddenly unwell during a session should prompt stopping and alerting staff immediately, with staff managing the chamber safely. Call 999 for severe difficulty breathing, a tight or heavy chest, or sudden confusion. Contact NHS 111 for urgent symptoms that are not immediately life-threatening, and a GP for persistent, non-urgent symptoms after a session.
How to judge a claim fairly
A credible explanation makes its boundaries visible. It identifies the population studied, distinguishes measured outcomes from proposed mechanisms, and acknowledges uncertainty. These checks help separate a research finding from a commercial promise:
Identify the exact claim: symptom improvement, a laboratory change, better performance and longer life require different evidence. Check what 'approved' refers to: a device, a named indication, a guideline recommendation or a funding decision. Look for human comparisons and meaningful outcomes, rather than relying on animal findings, testimonials or before-and-after measurements. Ask whether independent research supports the finding and whether benefits persist beyond short follow-up. Check that harms, withdrawals and uncertainties receive attention alongside favourable results. Emerging does not mean impossible, and recognised does not mean certain for every patient. The appropriate level of confidence follows the evidence for the exact claim. A clinical success in one condition cannot carry an unrelated longevity promise, however plausible the mechanism sounds.
This lesson is general education, not medical advice or a recommendation to use or avoid hyperbaric treatment. Decisions about hyperbaric oxygen belong with a qualified clinician.
Related in this classroom Related in other classrooms The studies behind this page Hyperbaric oxygen therapy indications - Undersea and Hyperbaric Medical Society, 15th editionFollow instructions for safe use of hyperbaric oxygen therapy devices - US Food and Drug Administration, 2025Further reading
Sources for this classroom
Educational content only. Not medical advice, diagnosis or treatment. Always consult a qualified healthcare professional before changing your health regimen.